National Pension Service Boosts Stock Position in Bristol Myers Squibb Company $BMY

National Pension Service boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.0% during the third quarter, Holdings Channel reports. The firm owned 5,106,519 shares of the biopharmaceutical company’s stock after acquiring an additional 244,970 shares during the quarter. National Pension Service’s holdings in Bristol Myers Squibb were worth $230,304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Trifecta Capital Advisors LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at about $25,000. Harbor Capital Advisors Inc. increased its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the period. REAP Financial Group LLC raised its stake in Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 428 shares in the last quarter. Finally, DHJJ Financial Advisors Ltd. lifted its holdings in Bristol Myers Squibb by 51.9% in the second quarter. DHJJ Financial Advisors Ltd. now owns 781 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 267 shares during the period. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. HSBC reaffirmed a “hold” rating and issued a $53.00 price target on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $57.00 price objective (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Citigroup restated a “neutral” rating and set a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Tuesday. Finally, Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has a consensus rating of “Hold” and a consensus price target of $57.43.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $55.03 on Friday. The business has a fifty day moving average price of $53.41 and a 200-day moving average price of $48.66. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The company has a market capitalization of $112.02 billion, a PE ratio of 18.59, a PEG ratio of 0.17 and a beta of 0.29. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. Bristol Myers Squibb’s revenue for the quarter was up 2.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.80 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date of this dividend is Friday, January 2nd. Bristol Myers Squibb’s payout ratio is 85.14%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.